Skip to content

Drug injury and delayed tumor loss

How does injury to proliferating tumor propagate through dying-cell stages? Explore fixed regimens and bounded dose-amplitude optimization in normalized benchmark units. No clinical dose, patient prediction, global optimum, or paper-figure agreement is claimed.

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How does exposure affect modeled tumor growth and delayed loss?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Lower exposure

How does injury to proliferating tumor propagate through dying-cell stages?

0–30 day

Scenario details

Lower exposure

How does injury to proliferating tumor propagate through dying-cell stages?

Readouts

Tumor total · dimensionless
Explore fixed regimens and bounded dose-amplitude optimization in normalized benchmark units. No clinical dose, patient prediction, global optimum, or paper-figure agreement is claimed.
Proliferating tumor · dimensionless
Explore fixed regimens and bounded dose-amplitude optimization in normalized benchmark units. No clinical dose, patient prediction, global optimum, or paper-figure agreement is claimed.
Drug exposure · dimensionless
Explore fixed regimens and bounded dose-amplitude optimization in normalized benchmark units. No clinical dose, patient prediction, global optimum, or paper-figure agreement is claimed.

Study purpose

  • How does injury to proliferating tumor propagate through dying-cell stages?

Assumptions

  • Regimens and dose optimization use normalized benchmark units. Optimization does not establish a global optimum.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Turnover / binding

Drug elimination rate

1/day

Suggested: 1.27–3.8. You can explore beyond this range.

2.53 → —

Drug-induced tumor injury coefficient

1/day

Suggested: 0.00385–0.0116. You can explore beyond this range.

0.0077 → —

Dying-cell transit rate

1/day

Suggested: 0.333–0.999. You can explore beyond this range.

0.666 → —
Simulation time
day
day
30 → 168

Time between reported samples.

day
0.1 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Optimize dose amplitudes

Administration times and model parameters stay fixed. Adjust starting amplitudes within the declared bounds, then compare the optimized response with the target.

Fixed-time benchmark amplitude optimization; not a clinical regimen or a paper-optimum reproduction.

Sign in to preview and run dose optimization.

Biology

How does injury to proliferating tumor propagate through dying-cell stages?

How does injury to proliferating tumor propagate through dying-cell stages?

Model details

8 parameters · 6 states · 6 equations · 3 derived outputs

Classification & API access
Therapeutic
generic tumor-injury agent
Modality
Other biologic or therapeutic modality
Target
proliferating tumor population
Disease / scope
Generic tumor growth and drug-injury research
ParameterDefaultUnitDescription
Apparent distribution volumeV2.79—Benchmark volume ratio
Growth guardgrowth_guard1e-161/daygrowth_guard
Absorption rate constantka51/dayAbsorption rate
Elimination rate constantkel2.531/dayDrug elimination rate
Drug induced tumor injury coefficientkpot0.00771/dayDrug-induced tumor injury coefficient
Dying cell transit ratekt0.6661/dayDying-cell transit rate
Initial tumor growth ratelam00.1941/dayInitial tumor growth rate
Limiting tumor growth ratelam10.2461/dayLimiting tumor growth rate

Related models

Drug-stimulated biomarker turnoverBispecific exposure and ternary binding

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics